The survival rate of advanced NSCLC is poor, with a global 5-year survival rate below 20%.[1] Currently, immune checkpoint inhibitors, including programmed cell death receptor-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), have evolved as the most hopeful and attractive therapeutic modalities for NSCLC.[2] In this article, we describe a patient with NSCLC who showed a durable response to toripalimab (PD-1 inhibitor) combined with radiotherapy after failure of first-line chemotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.